# CCI-779 in Treating Patients With Mantle Cell Non-Hodgkin's Lymphoma

> **NCT00033267** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 27 (actual)

## Conditions studied

- Recurrent Mantle Cell Lymphoma

## Interventions

- **DRUG:** temsirolimus

## Key facts

- **NCT ID:** NCT00033267
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-04
- **Primary completion:** 2006-02
- **Final completion:** 2008-02
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2014-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00033267

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00033267, "CCI-779 in Treating Patients With Mantle Cell Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00033267. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*